Brexit: MHRA Grilling Gives A Regulator's View Of The Stakes
This article was originally published in SRA
Executive Summary
Many of those in the life sciences sector who would be affected by a possible UK departure from the EU, including industry, scientists, the academic community and lawyers, have been happy to make their views known as to the likely effects. The voice of the drug regulators in this debate, though, has been understandably muted.
You may also be interested in...
UK Votes To Leave The EU – Where Next For The Life Sciences?
UK vote to leave the EU opens the prospect of years of negotiations over the union's future relationship with one of its most valued member states.
The Brexit Effect: What Would It Mean For Europe's Future Patent System?
UK referendum on whether to remain in EU will take place around the time that the Unified Patent Court is expected to launch.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.